Leading South Korean antibody-drug conjugate (ADC) specialist LigaChem Biosciences has made a $25m investment for an initial 26.6% equity stake in existing partner IKSUDA Therapeutics, and secured the right to buy shares from other current major shareholders to eventually take control of the UK-based ADC specialist.
LigaChem Eyes Future Acquisition Of IKSUDA Following 26.6% Stake
Part Of Strategy To Become Global ADC Player
South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.
